These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 21105835)

  • 1. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
    Kilic S; Yilmaz N; Zulfikaroglu E; Erdogan G; Aydin M; Batioglu S
    Gynecol Endocrinol; 2011 Sep; 27(9):622-9. PubMed ID: 21105835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
    Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
    Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F; Zamani MM; Heshmat R; Moini nia F
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment.
    Heutling D; Schulz H; Nickel I; Kleinstein J; Kaltwasser P; Westphal S; Mittermayer F; Wolzt M; Krzyzanowska K; Randeva H; Schernthaner G; Lehnert H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):82-90. PubMed ID: 17986642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
    Diamanti-Kandarakis E; Spina G; Kouli C; Migdalis I
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4666-73. PubMed ID: 11600523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
    Li M; Yang M; Zhou X; Fang X; Hu W; Zhu W; Wang C; Liu D; Li S; Liu H; Yang G; Li L
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
    Morin-Papunen L; Rautio K; Ruokonen A; Hedberg P; Puukka M; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4649-54. PubMed ID: 14557435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome.
    Rajagopal G; Reddy AP; Venkata Harinarayan C; Suresh V; Bitla A; P V L N Rao S; Sachan A
    Metab Syndr Relat Disord; 2012 Aug; 10(4):273-9. PubMed ID: 22468948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.
    Taskin MI; Bulbul E; Adali E; Hismiogulları AA; Inceboz U
    Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome.
    Yildizhan R; Ilhan GA; Yildizhan B; Kolusari A; Adali E; Bugdayci G
    Fertil Steril; 2011 Jul; 96(1):246-50. PubMed ID: 21600576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome.
    Zhai J; Liu CX; Tian ZR; Jiang QH; Sun YP
    Biol Reprod; 2012 Aug; 87(2):29. PubMed ID: 22572996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS).
    Ozgurtas T; Oktenli C; Dede M; Tapan S; Kenar L; Sanisoglu SY; Yesilova Z; Yenen MC; Erbil MK; Baser I
    Atherosclerosis; 2008 Oct; 200(2):336-44. PubMed ID: 18281049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
    J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
    Singh S; Akhtar N; Ahmad J
    Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.